This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Dr Purdon and colleagues should be commended on their efforts to study the highly important issue of long-term cognitive changes when patients with schizophrenia are treated with different antipsychotic drugs.¹ Their report raises many issues that we discuss in this letter.

In addition to assessing psychopathology, all patients were studied using a neuropsychological test battery measuring cognitive functions in 6 domains (motor skills, attention, verbal fluency and reasoning, nonverbal fluency and construction, executive skills, and immediate recall). From these 6 domains, the authors computed a general cognitive index. They conclude that olanzapine has statistically significant advantages over both risperidone and haloperidol in the general cognitive index. All statistically significant differences between groups with regard to the 6 domains of cognitive functions fell victim to an correction for multiple testing. In a within-group analysis, olanzapine showed significant advantages in only 1 of 6 specific cognitive domains (immediate recall) and in 1 . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?